NAMSW — NewAmsterdam Pharma Co N.V.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1936258 ·
Last close
$11.40
Market Cap
—
52W High
$30.45
52W Low
$11.37
ADV30
1,603
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 3,701,000 | — | -64,864,000 | -64,135,000 | 704,452,000 | 424,151,000 | 73,030,000 |
| Mar 2026 | 3,040,000 | — | -58,420,000 | -48,441,000 | 732,643,000 | 457,607,000 | 67,421,000 |
| Dec 2025 | 32,000 | — | -65,980,000 | -74,923,000 | 769,284,000 | 490,002,000 | 85,853,000 |
| Sep 2025 | 348,000 | — | -55,143,000 | -72,005,000 | 786,427,000 | 538,407,000 | 58,357,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-143,462,000
Investing CF
$-34,906,000
Financing CF
$41,682,000
CapEx
$-260,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-874,966,000
Inventory
—
Receivables
$5,345,000
ST Investments
$209,703,000
EBIT TTM
$-244,407,000
Pretax Income TTM
$-259,504,000
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$7,121,000
EBITDA
$-244,163,008
Free Cash Flow
$-45,358,376
Enterprise Value
—
Total Cash
$633,854,016
Total Debt
$82,000
Shares Out
—
Trailing EPS
—
Book Value
$5.37
ROE
-36.8%
ROA
-20.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 22,503,000 | -225,683,000 | -203,819,000 | 769,284,000 | 85,853,000 | 683,431,000 | -147,783,000 |
| Dec 2024 | 45,563,000 | -176,289,000 | -241,598,000 | 864,620,000 | 107,120,000 | 757,500,000 | -158,564,000 |
| Dec 2023 | 14,090,000 | -182,967,000 | -176,937,000 | 347,097,000 | 58,704,000 | 288,393,000 | -141,218,000 |
| Dec 2022 | 102,694,000 | -3,557,000 | -22,634,000 | 478,497,000 | 48,431,000 | 430,066,000 | 10,665,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.06T | $1183.46 | — |
| JNJ | JOHNSON & JOHNSON | $653.61B | $271.22 | — |
| ABBV | AbbVie Inc. | $467.12B | $264.34 | — |
| MRK | Merck & Co., Inc. | $367.07B | $148.78 | — |
| NVS | NOVARTIS AG | $276.48B | $145.46 | — |
News headlines (Yahoo Finance, 1h cache)
NewAmsterdam Pharma (NAMS) Wins EU Approvals. Can Cholesterol Pills Drive Royalties?
2026-09-23 01:20 · Yahoo
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
2026-09-21 13:00 · Yahoo
NewAmsterdam Pharma (NAMS) Stock Looks Above Fair Value After Its 139% Run
2026-09-20 04:18 · Yahoo
Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?
2026-09-15 12:47 · Yahoo
How Novartis' Double-Stacked Failures Reverberated Through Biopharma
2026-09-08 20:26 · Yahoo
Novartis Trial Failure Sparks Biopharma Options Frenzy
2026-09-08 16:07 · Yahoo
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-03 20:01 · Yahoo
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September
2026-09-02 12:00 · Yahoo
NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
2026-08-26 12:00 · Yahoo
NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears
2026-08-05 17:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.